Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 2
1963 1
1967 4
1968 1
1969 1
1970 1
1971 1
1972 1
1975 1
1980 2
1983 1
1984 1
1985 8
1986 4
1987 3
1988 2
1989 3
1991 5
1992 11
1993 2
1994 7
1995 5
1996 5
1997 2
1998 12
1999 15
2000 13
2001 10
2002 4
2003 11
2004 8
2005 4
2006 2
2007 9
2008 7
2009 15
2010 15
2011 23
2012 17
2013 22
2014 31
2015 33
2016 13
2017 26
2018 27
2019 24
2020 19
2021 34
2022 28
2023 27
2024 21

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

476 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial.
Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Ogita M, Suwa S, Isawa T, Domei T, Yamaji K, Tatsushima S, Watanabe H, Ohya M, Tokuyama H, Tada T, Sakamoto H, Mori H, Suzuki H, Nishikura T, Wakabayashi K, Hibi K, Abe M, Kawai K, Nakao K, Ando K, Tanabe K, Ikari Y, Morino Y, Kadota K, Furukawa Y, Nakagawa Y, Kimura T; STOPDAPT-2 ACS Investigators. Watanabe H, et al. JAMA Cardiol. 2022 Apr 1;7(4):407-417. doi: 10.1001/jamacardio.2021.5244. JAMA Cardiol. 2022. PMID: 35234821 Free PMC article. Clinical Trial.
STING, a cytosolic DNA sensor, plays a critical role in atherogenesis: a link between innate immunity and chronic inflammation caused by lifestyle-related diseases.
Pham PT, Fukuda D, Nishimoto S, Kim-Kaneyama JR, Lei XF, Takahashi Y, Sato T, Tanaka K, Suto K, Kawabata Y, Yamaguchi K, Yagi S, Kusunose K, Yamada H, Soeki T, Wakatsuki T, Shimada K, Kanematsu Y, Takagi Y, Shimabukuro M, Setou M, Barber GN, Sata M. Pham PT, et al. Among authors: wakatsuki t. Eur Heart J. 2021 Nov 7;42(42):4336-4348. doi: 10.1093/eurheartj/ehab249. Eur Heart J. 2021. PMID: 34226923
Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA).
Tanaka A, Taguchi I, Hisauchi I, Yoshida H, Shimabukuro M, Hongo H, Ishikawa T, Kadokami T, Yagi S, Sata M, Node K; DIANA study investigators. Tanaka A, et al. Eur J Med Res. 2023 Jul 17;28(1):238. doi: 10.1186/s40001-023-01208-1. Eur J Med Res. 2023. PMID: 37461063 Free PMC article.
An Aspirin-Free Strategy for Immediate Treatment Following Complex Percutaneous Coronary Intervention.
Yamamoto K, Natsuaki M, Watanabe H, Morimoto T, Obayashi Y, Nishikawa R, Ando K, Suwa S, Isawa T, Takenaka H, Ishikawa T, Tamura T, Kawahatsu K, Hayashi F, Akao M, Serikawa T, Mori H, Kawamura T, Hagikura A, Shibata N, Ono K, Kimura T; STOPDAPT-3 Investigators. Yamamoto K, et al. JACC Cardiovasc Interv. 2024 May 13;17(9):1119-1130. doi: 10.1016/j.jcin.2024.03.017. JACC Cardiovasc Interv. 2024. PMID: 38749592
Efficacy and Safety of Trastuzumab Deruxtecan and Nivolumab as Third- or Later-Line Treatment for HER2-Positive Advanced Gastric Cancer: A Single-Institution Retrospective Study.
Shimozaki K, Nakayama I, Takahari D, Nagashima K, Yoshino K, Fukuda K, Fukuoka S, Osumi H, Ogura M, Wakatsuki T, Ooki A, Shinozaki E, Chin K, Yamaguchi K. Shimozaki K, et al. Among authors: wakatsuki t. J Gastric Cancer. 2023 Oct;23(4):609-621. doi: 10.5230/jgc.2023.23.e41. J Gastric Cancer. 2023. PMID: 37932227 Free PMC article.
Aspirin-free strategy for percutaneous coronary intervention in acute coronary syndrome based on the subtypes of acute coronary syndrome and high bleeding risk: the STOPDAPT-3 trial.
Obayashi Y, Natsuaki M, Watanabe H, Morimoto T, Yamamoto K, Nishikawa R, Ando K, Suwa S, Isawa T, Takenaka H, Ishikawa T, Tokuyama H, Sakamoto H, Fujita T, Nanasato M, Okayama H, Nishikura T, Kirigaya H, Nishida K, Ono K, Kimura T; STOPDAPT-3 investigators. Obayashi Y, et al. Eur Heart J Cardiovasc Pharmacother. 2024 Aug 14;10(5):374-390. doi: 10.1093/ehjcvp/pvae009. Eur Heart J Cardiovasc Pharmacother. 2024. PMID: 38285607 Clinical Trial.
476 results